Analysts' Actions -- Alnylam, AutoNation, Tesla and More

RATINGS CHANGES

Alnylam (ALNY) - Get Report was downgraded to equal-weight from overweight at Barclays. $50 price target. The company has seen multiple pipeline setbacks, Barclays said. 

Alnylam was downgraded to neutral from overweight at JPMorgan. $51 price target. Revusiran blow is a big hit to the company's potential growth, JPMorgan said. 

Alnylam was downgraded to market perform at Leerink Partners. $40 price target. Revusiran failure adds risk to the company's clinical pipeline, Leerink said. 

AutoNation (AN) - Get Report was upgraded to neutral from sell at Goldman Sachs. $49 price target. The valuation is more attractive, as the stock has trailed the market by 15% over the past seven months, Goldman said. 

American Express (AXP) - Get Report was downgraded to reduce from neutral at Nomura. $56 price target. The company will likely continue to lose market share and miss revenue expectations, Nomura said. 

GigPeak (GIG) - Get Report was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: GIG.

Imperva (IMPV) - Get Report was downgraded to neutral from buy at DA Davidson. $55 price target. Despite potential acquisition, there appears to be little upside to valuation, Davidson said. 

Ionis (IONS) - Get Report was upgraded to outperform at BMO Capital. $48 price target. The company should benefit from pain at competitor Alnylam, BMO said. 

Moog (MOG.A) was downgraded to hold at TheStreet Ratings. You can view the full analysis from the report here: MOG.A.

Tesla (TSLA) - Get Report was downgraded to neutral from buy at Goldman Sachs. $185 price target. Acquisition adds risk to the model and leaves little room for potential production delays, Goldman said. 

This article was written by a staff member of TheStreet.